Table of Contents Table of Contents
Previous Page  E172 1030 Next Page
Information
Show Menu
Previous Page E172 1030 Next Page
Page Background

Letter to the Editor

Re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al.

The Single-parameter, Structure-based IsoPSA Assay

Demonstrates Improved Diagnostic Accuracy for

Detection of Any Prostate Cancer and High-grade

Prostate Cancer Compared to a Concentration-based

Assay of Total Prostate-specific Antigen: A Preliminary

Report. Eur Urol 2017;72:942–9

The Most Appropriate IsoPSA Cutoff for Diagnosis of

Prostate Cancer

In their article on determination of IsoPSA cutoff value for

the diagnosis of prostate cancer, Klein et al

[1]

reported a

cutoff point with sensitivity (Se) of 90% and specificity (Sp) of

48% to discriminate men with and without prostate cancer.

However, to determine the most appropriate cutoff value

for a test with continuous results such as IsoPSA, we need to

take into account the pretest probability (

P

pr

) of the disease

(prostate cancer) and an estimate of the cost of a false-

negative relative to a false-positive test result (

C

)

[2,3]

. We

have shown that maximizing the weighted number needed

to misdiagnose (wNNM) corresponds to the most appro-

priate test cutoff value

[2,4]

:

wNNM

¼

1

C P

pr

1 Se

ð

Þ þ

1

P

pr

1 Sp

ð

Þ

To calculate this index, we need to know estimates of

P

pr

and

C

, as well as Se and Sp values corresponding to each

point on the receiver operating characteristic (ROC) curve.

Klein et al

[1]

reported that the prevalence of prostate

cancer in their sample was 53%.

If we do not diagnose a patient with prostate cancer

(false-negative result), he returns in a worse condition

needing more extensive treatment. Conversely, designating

a healthy man as having prostate cancer (false-positive

result) would result in unnecessary tests, waste of

resources, time, and money, and psychological trauma to

him and his family members. Let us assume that the costs

associated with a false-negative result are 15 times those

for a false-positive result (

C =

15)

[5]

. To determine Se and

Sp corresponding to each point on the ROC curve (Fig. 2A in

[1] )

, we scanned the figure using a digitizer (GTCO CalComp,

Scottsdale, AZ, USA).

The most appropriate cutoff value (maximum wNNM)

corresponds to a point at Se = 99% and Sp = 6%

( Fig. 1

)

[2] .

This value, however, changes depending on the

condition under which we want to use it. For example,

assuming prevalence of 5% (instead of 53%), the cutoff value

corresponds to a point at Se = 83% and Sp = 65% (retaining

C

= 15); assuming prevalence of 53%, but

C

= 5 (instead of

15), the most appropriate cutoff value corresponds to a

point at Se = 93% and Sp = 44%

( Fig. 1 )

. Having access to the

raw data, the authors can determine the IsoPSA levels

corresponding to each of the aforementioned points. Similar

analyses can be performed to determine the most

E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) e 1 7 2 – e 1 7 3

available at

www.scienced irect.com

journal homepage:

www.europeanurology.com

[(Fig._1)TD$FIG]

Fig. 1 – Receiver operating characteristic curve for discriminating men

with and without prostate cancer, regenerated from parts of Figure 2A

in the article by Klein et al

[1]

. The open red circle is the point they

reported for discrimination. However, if the data presented in the

article (prevalence of 53%) are used, assuming

C

= 15, the most

appropriate cutoff value corresponds to another point (the green

diamond). Using the same assumptions but

C

= 5 (instead of 15), the

most appropriate cutoff value corresponds to another point (red solid

circle). Assuming a prostate cancer prevalence of 5% (instead of 53%)

and

C

= 15, the point corresponds to the orange solid square. Cutoff

values were calculated following Habibzadeh et al

[2]

.

DOI of original article:

http://dx.doi.org/10.1016/j.eururo.2017.03.025

.

http://dx.doi.org/10.1016/j.eururo.2017.06.028

0302-2838/

#

2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.